1659 related articles for article (PubMed ID: 16904046)
1. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
[TBL] [Abstract][Full Text] [Related]
4. The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review.
Bryant J; Brodin H; Loveman E; Payne E; Clegg A
Health Technol Assess; 2005 Sep; 9(36):1-150, iii. PubMed ID: 16153353
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
[TBL] [Abstract][Full Text] [Related]
6. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
10. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.
Lynd LD; O'Brien BJ
J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S99-103. PubMed ID: 12950529
[TBL] [Abstract][Full Text] [Related]
12. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
[TBL] [Abstract][Full Text] [Related]
13. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
Parkes J; Bryant J; Milne R
Health Technol Assess; 2000; 4(26):1-69. PubMed ID: 11086270
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the ventricular assist device programme in the UK.
Sharples L; Buxton M; Caine N; Cafferty F; Demiris N; Dyer M; Freeman C
Health Technol Assess; 2006 Nov; 10(48):1-119, iii-iv. PubMed ID: 17134596
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.
Thijssen J; van den Akker van Marle ME; Borleffs CJ; van Rees JB; de Bie MK; van der Velde ET; van Erven L; Schalij MJ
Pacing Clin Electrophysiol; 2014 Jan; 37(1):25-34. PubMed ID: 23998638
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
19. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
